The Risk of Side Effects of a Monoclonal Anti-Amyloid Drug

The proposed benefit from the clinical trials for people receiving aduni, the monoclon about against the ameloid, showed what many would consider insignificant progress or games. This is one time they went against the advice of the review panel. And when the fta approved it, i want to say two, maybe three of the reviewers so resigned tos the han seen. His happiness is ridiculous. But my concern is that it's going to give false hope to a lot of patients out there. I've seen that already, that people think, now, oh my god, we've got a ent. Finally it'll work. Most of the scientists in this field aren't very scept